Login / Signup

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.

Vijay Maruti PatilVanita NoronhaNandini Sharrel MenonAjay SinghSarbani Ghosh LaskarAshwini BudrukkarAtanu BhattacharjeeMonali SwainVijayalakshmi MathrudevKavita NawaleArun BalajiZoya PeelayMitali AloneShruti PathakAbhishek MahajanSuman KumarNilendu PurandareArchi AgarwalAmeya D PuranikShantanu PendseMonica Reddy YallalaHarsh SahuVenkatesh KapuSayak DeyJatin ChoudharyMadala Ravi KrishnaAlok ShettyNaveen KaruvandanRahul RavindRahul RaiKunal JobanputraPankaj ChaturvediPrathamesh S PaiDevendra ChaukarSudhir Vasudevan NairShivakumar ThiagarajanKumar Prabhash
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC.
Keyphrases
  • phase iii
  • locally advanced
  • open label
  • clinical trial
  • rectal cancer
  • double blind
  • phase ii
  • squamous cell carcinoma
  • placebo controlled
  • radiation therapy
  • radiation induced